GIA
LRMR icon

Gem Investment Advisors’s Larimar Therapeutics LRMR Stock Holding History

Gem Investment Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$975K Sell
319,519
-534,711
-63% -$2.12M 0.6% 23
2026
Q1 		$3.84M Buy
854,230
+573,370
+204% +$2.29M 3.78% 13
2025
Q4 		$1.07M Buy
+280,860
New +$1.09M 1.01% 21

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Gem Investment Advisors's LRMR Position: Q2 2026 in Review

Gem Investment Advisors reduced its Larimar Therapeutics (LRMR) stake by 63% in Q2 2026, selling an estimated $2.12M and leaving 319,519 shares worth $975K. The position accounts for 0.6% of the portfolio, ranked #23.

Gem Investment Advisors first reported a position in LRMR in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.84M in Q1 2026. 161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Gem Investment Advisors held 319,519 shares of Larimar Therapeutics worth $975K as of Q2 2026.
  • Gem Investment Advisors sold 534,711 Larimar Therapeutics shares in Q2 2026, an estimated $2.12M.
  • Larimar Therapeutics made up 0.6% of Gem Investment Advisors's portfolio in Q2 2026, its #23 holding.
  • Gem Investment Advisors first reported a position in Larimar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Gem Investment Advisors's Larimar Therapeutics position peaked at $3.84M in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Gem Investment Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.